Lyra Therapeutics, Inc.
LYRA
$7.47
$0.131.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.99% | 22.15% | 7.53% | 75.33% | -114.37% |
| Total Depreciation and Amortization | -0.78% | -15.23% | 287.18% | -73.10% | 6.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -100.00% | -- |
| Total Other Non-Cash Items | 9.82% | -50.66% | 53.39% | -95.67% | 1,947.84% |
| Change in Net Operating Assets | 85.10% | 43.17% | 59.92% | -303.15% | 297.15% |
| Cash from Operations | 25.47% | 22.11% | 30.03% | 18.81% | 11.02% |
| Capital Expenditure | -- | -- | 213.73% | 73.98% | 90.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 242.69% | -77.48% | 263.50% |
| Cash from Investing | -- | -- | 245.55% | -77.50% | 360.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -99.90% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 76.53% | 42.01% |
| Cash from Financing | -- | -- | 95.65% | 74.16% | -101.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 77.93% | -152.70% | 307.01% | -150.32% | 370.51% |